MENLO PARK, Calif.,
Oct. 14, 2015 /PRNewswire/
-- Research being presented at the Skin Disease Education
Foundation's 11th Annual Women's & Pediatric
Dermatology Seminar shows that a unique, hydrophilic drug
formulation may offer a breakthrough in the treatment of acne.
The investigational drug product, called BPX-01 developed by
specialty pharmaceutical company BioPharmX Corporation (NYSE MKT:
BPMX), is the first and only stable hydrophilic topical gel of its
kind for an antibiotic that can more effectively deliver
therapeutic concentrations to the skin's target anatomy where acne
develops.
Existing topical acne medications are lipophilic formulations
that ensure stability, but compromise effectiveness because the
antibiotic is not solubilized and is less effective in reaching the
target tissue.
Some lipophilic formulations use substances or combinations of
substances such as mineral oil, beeswax, soybean oil, cetostearyl
alcohol, etc., all of which occlude pores and are
counter-productive for acne treatment by further limiting drug
penetration into the skin. To compensate for the lipophilic
formulations' limitations, drug products often have significantly
increased drug dosages resulting in unnecessary or undesirable side
effects.
"Our studies indicate that BPX-01 is more effective at
delivering antibiotic into the skin than drug in a lipophilic
formulation, suggesting that lower doses of antibiotic can provide
superior efficacy over other formulations with higher doses," said
Kin F. Chan, Ph.D., executive vice president of research and
development at BioPharmX Corporation. "Usability studies indicate
that BPX-01 distributes evenly, is not sticky and does not occlude
or irritate the skin, indicating that it could offer a significant
advancement in the treatment of acne."
The BioPharmX study's findings will be presented at the
Dermatology Seminar in Newport Beach,
Calif., Oct. 23-24, 2015.
The American Academy of Dermatology calls acne the "most common
skin condition in the United States," affecting 40 to 50 million
Americans at any given moment. The disease can cause permanent
scarring, low self-esteem, depression and anxiety.
The condition is typically treated with oral antibiotics,
sometimes in combination with topical products. Oral
antibiotics often lead to antibiotic resistance and other side
effects making them often ineffective or not tolerated. An
effective and easy to use topical formulation addresses a very
large unmet need.
About BioPharmX™ Corporation
BioPharmX Corporation
(NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical
company, which seeks to provide products through proprietary
platform technologies for prescription, over-the-counter ("OTC"),
and supplement applications in the health and wellness markets,
including women's health and dermatology. To learn more about
BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, or the Securities Act, and Section 21E of the Securities
Exchange Act of 1934, as amended, or the Exchange Act, which are
subject to the "safe harbor" created by those section.
This press release contains forward-looking statements about the
company's expectations, plans, intentions, and strategies,
including, but not limited to, statements regarding, including with
respect to: the success of the commercialization of VI2OLET iodine,
the effectiveness of BPX01, the timing with respect to filing an
IND and clinical trials for BPX01, the release of key data for
BPX01, the release of key data and the successful completion of
multi-site IRB studies for BPX03 and the successful completion of
the private placement with Korea Investment Partners Overseas
Expansion Platform Fund. These forward-looking statements may be
identified by words such as "plan", "expect," "anticipate,"
"believe," or similar expressions that are intended to identify
such forward-looking statements. These forward-looking
statements involve risks and uncertainties, as well as assumptions,
which, if they do not fully materialize or prove incorrect, could
cause our results to differ materially from those expressed or
implied by such forward-looking statements. The risks and
uncertainties include those described in the company's filings with
the Securities and Exchange Commission. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements. The forward-looking
statements included in this news release are made only as of the
date hereof and the company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities law.
BioPharmX and Violet are registered trademarks of BioPharmX,
Inc.
Photo - http://photos.prnewswire.com/prnh/20151013/276675
Logo -
http://photos.prnewswire.com/prnh/20150711/235327LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/study-shows-novel-biopharmx-formulation-promises-breakthrough-in-acne-treatment-300159371.html
SOURCE BioPharmX Corporation